Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses

Fumiya Hongo 1*, Yasuhiro Yamada 1, Takashi Ueda 1, Terukazu Nakmura 1, Yoshio Naya 1, Kazumi Kamo 1, Koji Okihara 1, Yusuke Ichijo 2, Tsuneharu Miki 1, Kei Yamada 2 and Osamu Ukimura 1

Abstract

Background: Partial nephrectomy for small renal masses (SRM) may be useful for preserving renal function, but is technically more difficult than radical nephrectomy. Cryoablation may be performed under local anesthesia. The objective of the present study is to assess the safety and therapeutic efficacy of cryoablation with lipiodol marking for SRM.

Methods: Cryoablation therapy was performed on 42 patients under local anesthesia. Their median age was 74 years (31–91). The median tumor diameter was 21 mm (10–42). Responses to the treatment were evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) by contrast-enhanced CT. In six patients (14.3%) for whom it was not possible to use contrast medium, plain CT findings were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST).

Results: Twenty-nine (69%) and five (12%) patients achieved complete responses (CR) and partial responses (PR), respectively, while four (10%) and four (10%) patients each had stable disease (SD) and progressive disease (PD) after the first course of therapy. A second course of cryoablation therapy with lipiodol marking was performed on three out of four patients with PD after the first course of therapy, and resulted in a total of 32 patients achieving CR (76%). Four (36.4%) out of 11 patients for whom lipiodol marking was not conducted had PD, whereas none of the 31 patients for whom lipiodol marking was conducted had PD. All grade complications were reported in 11 (24.4%) patients while grade 3 in two (4.4%) patients. 11 (24.4%) A significant difference was observed in postoperative hemorrhagic events in all grades (18% in patients undergoing cryoablation without lipiodol marking vs. 0% in patients undergoing cryoablation without lipiodol marking).

Conclusions: Although further studies involving more patients are needed in order to evaluate long-term results, cryoablation therapy appears to be a useful treatment option for SRM. Preoperative marking with lipiodol was helpful for improving complication and survival rates with cryoablation.

Keywords: Ablation, Cryoablation, Lipiodol marking, Renal cell cancer, Small renal mass

Background

Renal function-preserving surgery has recently been recommended as a treatment for small renal cancer [1–3]. Percutaneous cryoablation therapy, which includes thermal ablation, for humans was initially reported by Uchida [4]. Laparoscopic cryoablation was subsequently conducted, and favorable outcomes were reported [5]. In Japan, cryoablation has been covered by national health insurance since 2011. We started to perform percutaneous cryoablation therapy for SRM in March 2013, and herein report our initial experience with this procedure.

Computed tomography (CT)- or magnetic resonance imaging (MRI)-guided puncture is conducted in cryoablation therapy. One of the advantages of CT-guided puncture is that it provides a broader space for puncture than MRI-guided puncture; however, it is more difficult
to recognize tumor margins with CT-guided puncture than with MRI-guided puncture. Plain CT-guided puncture is performed in our hospital. In some patients with submerged tumors or tumor margins that are difficult to recognize, marking with lipiodol is conducted prior to cryoablation therapy.

Lipiodol is a lipid-soluble contrast material that is used for lymphangiography [6], hysterosalpingography [7], and transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma [8]. Since lipiodol remains in place for several days, it is easy to localize nodules using X-ray or CT fluoroscopy during surgery. In the present study, we examined the efficacy of cryoablation therapy for SRM and the usefulness of preoperative lipiodol marking.

**Methods**

**Patients**

In March 2013, our hospital started to perform cryoablation therapy on patients who were not indicated for radical surgery under general anesthesia because of active double cancer or complications or on those who did not wish to undergo surgery due to the presence of only one kidney or for some other reason. A preoperative staging imaging evaluation (chest to abdominal CT) was routinely performed on all patients. We retrospectively examined the efficacy of this procedure, adverse events, and post-treatment changes in renal function. Pre- and postoperative serum creatinine levels and adverse events in patients aged 75 years or older were compared with those in patients aged 74 years or younger. The present study was conducted in accordance with the Principles of Helsinki. This study protocol was approved by Institutional Review Board of Kyoto Prefectural University of Medicine. The Ethics board approval number was ERB-C-54-1. All patients included in this study provided informed consent for cryosurgery, accompanying standard care and the use of their data in research.

**Cryoablation methods**

The treatment plan was made by performing CT before ablation. A CryoHit® device (Galil Medical USA; Hitachi Medical Corporation, Japan) was employed. IceSeed® or IceRod® needles were used in accordance with the tumor diameter. One to three needles were used for ablation as one IceSeed® for less than 10 mm, 2 IceSeeds® for 10–12 mm, 3 IceSeeds® or 2 IceRods® for 13–20 mm, 3 IceRods® for 21–30 mm, and 4 IceRods® for 31–40 mm. The cryoprobe was introduced under CT fluoroscopic guidance (Vigor Laudator, Toshiba Medical System, Tokyo, Japan) after local anesthesia had been administered by a subcutaneous injection of 1% lidocaine.

The tumor site was cooled with argon gas and thawed with helium gas. The cryoablation area was monitored at appropriate times during puncture or cryoablation. Two cycles of cryoablation were then performed, with the first cycle typically lasting 10–15 min and the second 10 min. Passive thaw was performed between the ablation cycles, and active thaw was performed after the second cycle.

When the tumor was adjacent to peripheral organs, such as the intestinal tract, hydrodissection with physiological saline was performed in order to avoid injury. Transdiaphragmatic puncture with an artificial pneumothorax was conducted for transthoracic puncture. When the tumor was adjacent to the renal pelvis, a ureteral catheter was inserted in some patients, and the tumor site was perfused with warm physiological saline to avoid injury to the renal pelvic mucosa.

As a rule, percutaneous tumor biopsy using 18-gauge Max-Core® (BARD, USA) was performed for a histopathological diagnosis before or at the time of cryoablation because the tumor histology and grade of preoperative biopsy predicted the oncological outcomes of renal cryoablation [9]. Local anesthesia and the prophylactic administration of antibiotics were permitted as combined and supportive therapies.

Transarterial lipiodol marking was performed 1–3 days before cryoablation therapy when difficulties were associated with identifying the tumor location on plain CT. Transfemoral visceral arteriography was conducted using a standard angiographic approach. Selective catheterization of the tumor-feeding arteries was performed under fluoroscopic guidance. After confirming the presence of the catheter tip in the branches of the renal arteries feeding the tumor, lipiodol (Laboratoire Guerbet, Roissy, France) was manually injected (range, 0.2–0.4 mL) under fluoroscopy to make a lipiodol spot.

**Evaluation of efficacy**

Responses to the treatment were evaluated by performing contrast-enhanced CT after 6 months. Efficacy was evaluated based on the tumor response rate, namely, a complete response (CR) or partial response (PR), using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria [10, 11]. The mRECIST criteria incorporate amendments to the original RECIST criteria. Tumor responses were defined as: (i) CR: the disappearance of any intratumoral arterial enhancement in all target lesions; (ii) PR: at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking the baseline sum of the diameters of target lesions as the reference; (iii) stable disease (SD): any cases that do not qualify for either PR or progressive disease (PD); (iv) PD: An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started as the reference.
Efficacy was evaluated based on the tumor response rate, namely, CR or PR, using the mRECIST criteria.

Complications
The Clavien Classification of Surgical Complications was used for surgically related complications [12].

Statistical analysis
Relationships between clinicopathological characteristics and response rates were examined using the $\chi^2$ test. Changes in serum creatinine levels were examined using the $t$-test. Test results were considered significant at $P < 0.05$. All analyses were performed using JMP 10.0.2 (SAS®).

Results
Patients
Cryoablation therapy was performed on a total of 42 patients before December 2014 (Table 1). Their median age was 74 years (range, 31–91). The median tumor diameter was 24.1 mm (range, 10–42 mm).

Percutaneous renal biopsy was performed on 86% of patients (36/42), but was not mandatory. Biopsy data are shown in Table 1. A pathological diagnosis of renal cell cancer (RCC) was reached in 30 out of the 36 patients and benign tumor (AML) in one patient who underwent biopsy. In the other five patients, biopsy specimens were insufficient to make a pathological diagnosis.

Response
Treatment responses were evaluated using mRECIST based on contrast-enhanced CT findings (Table 2). In six patients (14.3%) for whom it was not possible to use contrast medium, plain CT findings were assessed according to RECIST. After the first course of therapy, 29 (69%) and five (12%) patients achieved complete responses (CR) and partial responses (PR), respectively, while four (10%) and four (10%) patients each had stable disease (SD) and progressive disease (PD). A second course of cryoablation therapy with lipiodol marking was performed on three out of the four patients with PD after the first course of therapy. CR was achieved in two patients and PR in 1. Final treatment responses were evaluated in 42 patients, including three who underwent two courses of cryoablation therapy. CR and PR were achieved in 32 and five patients, respectively. SD and PD were noted in four and one patients, respectively. one patient proved to have AML. The technical success rate was 98%.

Complications
There were 11 episodes (24.4%) of complications during a total of 45 courses of cryoablation therapy regardless of the grade. Grade 3 or higher adverse events were observed in two patients (4.4%). Intra- and postoperative complications included fever, hematoma, hematuria, pleural effusion, hydronephrosis, and ureteral perforation in 5, 1, 2, 1, 1, and 1 patient, respectively (Table 3). Grade 3 or higher adverse events were observed in two patients: G3a hydronephrosis and G3a ureteral injury. There were no lipiodol marking-related adverse events.

Renal function after cryoablation
Postoperative renal function was investigated based on serum creatinine levels 3 months after the treatment. Preoperative serum creatinine levels were $0.95 \pm 0.4$ in patients aged 74 years or younger and $1.19 \pm 0.61$ in those aged 75 years or older. These values 3 months

### Table 1

| Preoperative lipiodol marking | (+) ($n=31$) | (−) ($n=11$) | $p$ value |
|-----------------------------|-------------|--------------|-----------|
| Mean age (year, range)      | 74 (31–91)  | 71.5 (31–86) | 71.1 (49–91) | NS         |
| Gender (%)                  |             |              |           | NS         |
| Male                        | 33 (79%)    | 27           |           |
| Female                      | 9 (21%)     | 5            |           |
| Laterality (%)              |             |              |           | NS         |
| Right                       | 21 (50%)    | 15           | 6         |
| Left                        | 21 (50%)    | 16           | 5         |
| Tumor size (mm)             | 24.1 (10–42)| 27.8 (10–42) | 21.3 (15–34) | $p < 0.05$ |
| Biopsy performed in 36/42 (85.7%) | 28 | 8 | NS |
| RCC                         | 30 (87%)    | 24           | 6         |
| AML                         | 1 (4%)      | 0            | 1         |
| Inappropriate sample         | 5 (9%)      | 4            | 1         |
| PD (%)                      | 4 (36.4%)   | 0            | 4 (36.4%) | $p < 0.001$ |
| Post ablative hemorrhagic event (%) | 2 (18%) | 0 | 2 (18%) | $p < 0.05$ |
after surgery were 0.96 ± 0.46 and 1.20 ± 0.55, respectively. The rates of changes were −1 ± 10 and 3 ± 15%, respectively, which were not significantly different (p = 0.3282).

We conducted preoperative lipiodol marking before cryoablation therapy on 31 patients with guidance difficulties under plain CT. Baseline patient demographics and operative outcomes are listed in Table 1. No significance differences were observed in mean age (71.5 vs. 71.1), gender (male/female) (27/5 vs. 6/4), or tumor laterality (15/16 vs. 6/5). On the other hand, significant differences were detected in tumor sizes (27.8 mm (10–42) vs. 21.3 (15–34) mm).

A case of cryoablation therapy with preoperative lipiodol marking was shown (Fig. 1). The red circle indicates the primary tumor. (A) The right renal tumor was detected by a preoperative dynamic CT scan. (B) The tumor was easily detected by intraoperative plain CT after lipiodol marking. (C) A postoperative CT scan showed no enhancement in the cryoablated area. CR was achieved by cryoablation according to mRECIST.

Among all 42 patients, relapse was detected in four (36.4%) out of 11 patients for whom lipiodol marking was not conducted and was not observed in any (0%) of the 31 patients for whom lipiodol marking was conducted showed relapse, with a significant difference between with and without marking (p = 0.01). Moreover, a significant difference was detected in postoperative hemorrhagic events (18% vs. 0%) (p < 0.05) (Table 1).

No deaths occurred within 1 month of cryoablation therapy. Although one patient died during the follow-up period, her death was not related to cryoablation therapy; she died of primary disease (malignant lymphoma) 20 months after cryoablation therapy.

Patient survival was evaluated at a mean follow-up time of 17 (range, 6–26) months (SD, 6.13 months). One- and 2-year overall survival rates were 100 and 94.4%, respectively.

### Discussion

Nephrectomy has been performed as a standard treatment for renal cancer for a long time. However, the detection rate of SRM has increased with recent advances in diagnostic imaging procedures. A paradigm shift in treatment approaches to renal masses is underway, leading the AUA to release guidelines for the management of clinical stage 1 renal masses in 2009 for the first time [1]. Partial nephrectomy or ablative therapy for T1a renal cancer may be useful for preventing nephrectomy-related chronic kidney disease (CKD) [13, 14]. In elderly patients or patients with comorbidities, who are likely have a lower estimated glomerular filtration rate (eGFR), rapid reductions in renal function have been implicated in early death [15]. Therefore, not only partial nephrectomy, but also ablative therapy including cryoablation therapy, which may be performed under local anesthesia without renal ischemia, thereby facilitating the preservation of renal function, may be useful for patients with comorbidities and the elderly. In the present study, the impact of cryoablation therapy on renal function in patients aged 75 years or older was not significant.

Treatment options for SRM include ablation therapy. In our hospital, RFA therapy has been performed as advanced medical care and its usefulness has been reported [16, 17]. However, in Japan, RFA for renal tumors is not yet covered by national health insurance. Therefore, cryoablation therapy, which is covered by national health insurance, is primarily performed in our hospital.

CT- or MRI-guided puncture is optional as a percutaneous approach. Plain semi-real-time CT-guided puncture is performed in our hospital. However, the major limitation of plain CT is the difficulty associated with the localization of the tumor, when the tumor resembles

### Table 2 Efficacy of cryoablation. In three of four patients with PD after the first therapy, second cryoablation therapy with lipiodol marking was performed.

|                | No. of cases | CR  | PR  | SD  | PD  |
|----------------|--------------|-----|-----|-----|-----|
| mRECIST        | 36           | 32 (89%) | 3 (8%) | 0 (0%) | 1 (3%) |
| RECIST         | 6            | 0 (0%) | 2 (33%) | 4 (67%) | 0 (0%) |
| Total          | 42           | 32 (76%) | 5 (12%) | 4 (10%) | 1 (2%) |

### Table 3 Postoperative complication in 45 sessions of cryoablation according to Clavien-Dindo classification.

|                | <75 yo (n = 21, 23 sessions) | ≥75 yo (n = 21, 22 sesseions) | Total |
|----------------|-----------------------------|-------------------------------|-------|
| All grade      | Grade 3≤                     | Grade 3≤                      | Grade 3≤ |
| Fever          | 5 (22%)                     | 1 (4%)                       | 6 (27%) |
| Hematoma       | 2 (9%)                      | 3 (14%)                      | 5 (11%) |
| Hematuria      | 1 (4%)                      | 1 (4%)                       | 1 (5%)  |
| Pleural effusion | 1 (5%)                     | 1 (2%)                       | 1 (2%)  |
| Hydronephrosis | 1 (4%)                      | 1 (4%)                       | 1 (2%)  |
| Ureter perforation | 1 (5%)                     | 1 (5%)                       | 1 (2%)  |
the renal parenchyma, and, importantly, patients indicated for ablative therapy may have renal dysfunctions that are a contraindication for the frequent intraoperative use of a CT contrast agent. In order to overcome these limitations, we evaluated the usefulness of lipiodol marking to identify the tumor center prior to percutaneous cryoablation with plain CT guidance. In the selected patients with submerged tumors or those in whom the tumor margin was difficult to recognize, marking with lipiodol was conducted prior to cryoablation therapy. We previously reported the usefulness of preoperative lipiodol marking prior to the ablation of lung cancer [18]. The use of cryoablation therapy for renal cancer has facilitated accurate evaluations of target tumors, thereby improving the accuracy of the treatment. In contrast, cryoablation therapy may also be performed with the confirmation of tumor contours by administering contrast medium. However, the use of contrast medium needs to be avoided in patients with renal hypofunction. Furthermore, a previous study indicated that embolization prior to cryoablation therapy was useful for reducing the incidence of complications related to cryoablation therapy [19]. Regarding lipiodol marking, lipiodol with a gelatin sponge is transarterially infused. It may be useful for identifying the tumor location or its margin on CT-guided probe insertion and preventing hemorrhage-associated complications because it reduces intra-tumor blood flow.

When the tumor was adjacent to peripheral organs, such as the intestinal tract, hydrodissection [20], which is useful for avoiding thermal ablation-related intestinal injury, was performed. There were no intestinal injuries in any patients (0%).

In 115 tumors were treated using PCA, technical success rate was achieved in 97% by post-procedure CT (with and without IV contrast or MRI on POD 1). There was no evidence of local recurrence in 80 tumors that were followed for a mean of 13.3 months by CT imaging [21]. Kapoor et al. reported that the maximal and minimal percentages of cancer-specific survival were 100% and 84.3% in follow-ups of 11.4 months (median) and 64 months (mean), respectively, by reviewing a total of 2104 analyzed tumors from 2038 patients in the literature [22].

On the other hand, the timing of follow-ups after cryoablation therapy has not yet been established. One exception was the series by Gill and colleagues; the authors routinely performed biopsies 6 months post-CA. In this series, two out of 56 tumors were positive 6 months

Fig. 1 A case of cryoablation with preoperative lipiodol marking. The red circle indicates the primary tumor. a The right renal tumor was detected by a preoperative dynamic computed tomography (CT) scan. b The tumor was easily detected by intraoperative plain CT after lipiodol marking. c A postoperative CT scan showed no enhancement in the cryoablated area. A complete response was achieved by cryoablation according to the mRECIST criteria.
However, cryoablation therapy may be useful for elderly patients and those with complications. A percutaneous thermal ablation procedure for renal cancer appears to be a useful treatment option for SRM. In the present study, preoperative marking with lipiodol was helpful for achieving successful cryoablation.

There were several limitations in the present study. The total number of cases was too small to reach definite conclusions. In addition, complete preoperative histological information was unavailable, limiting the oncological outcomes. Furthermore, this was a retrospective study. Therefore, controlled randomized trials need to be designed that compare preoperative lipiodol marking followed by cryoablation and cryoablation without lipiodol marking.

**Conclusions**

The results of the present study suggest that cryoablation with preoperative lipiodol marking improves the safety and success rate of CT-guided cryoablation for SRM. This approach was even shown to be useful for patients with renal dysfunctions, who were likely contraindicated for the intraoperative use of a contrast agent to visualize renal tumors.

**Abbreviations**

CA: Cryoablation; CKD: Chronic kidney disease; CT: Computed tomography; eGFR: Estimated glomerular filtration rate; HCC: Hepatocellular carcinoma; Lipiodol: Ethiodized oil; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; MR: Magnetic resonance imaging; PCA: Percutaneous cryoablation; POD1: Post operative day 1; RCC: Renal cell cancer; SRM: Small renal masses; TACE: Transcatheter arterial chemoembolization; UPJ: Ureteropelvic junction

**Acknowledgments**

The authors thank Ms. Morikawa Y and Ms. Nakamura S for data acquisition and Ms. Katsurai M for organizing the follow-up schedule after the treatment.

**Funding**

None.

**Availability of data and materials**

The datasets generated during the current study are not publicly available in order to protect confidentiality.

**Authors’ contributions**

FH carried out cryosurgery on patients, collected and analyzed data, and wrote and drafted the manuscript, YY, TU, and YI carried out cryosurgery on patients, YN and IK participated in the acquisition of data, TN and KO participated in the design of the study and performed the statistical analysis, and TM, KY, and OU conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics and consent to participate**

This study protocol was approved by Institutional Review Board of Kyoto Prefectural University of Medicine. The Ethics board approval number is ERB-C-54-1. All patients included in this study provided informed consent for the use of their data in research.
Author details
1Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyō-ku, Kyoto 602-8566, Japan. 2Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Received: 11 August 2016 Accepted: 10 January 2017

References
1. Campbell SC, Novick AC, Beldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.
2. Ljungberg B, Bensalah K, Canfield S, et al. EAU Guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24. doi:10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21.
3. Fujikura T, Obara W, Committee for Establishment of the Clinical Practice Guidelines for the Management of Renal Cell Carcinoma; Japanese Urological Association. Evidence-based clinical practice guidelines for renal cell carcinoma (Summary–JUA 2007 Edition). Int J Urol. 2009;16:339–53. doi:10.1111/j.1442-2042.2008.02242.x.
4. Uchida M, Imade Y, Sugimoto K, et al. Percutaneous cryosurgery for renal tumours. Br J Urol. 1995;75:132–6. discussion 136–137.
5. Gill IS, Novick AC, Meraney AM, et al. Laparoscopic renal cryoablation in 32 patients. Urology. 2000;56:748–53. doi:10.1006/uroy.2000.0752-4.
6. Matsumoto T, Yamaami T, Kato T, et al. The effectiveness of lymphangiography as a treatment method for various style leakages. Br J Radiol. 2009;82:286–90.
7. Johnson NP, Farquhar CM, Haddinen WE, et al. The FLUSH trial–flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomized trial. Hum Reprod. 2004;19:2043–51.
8. Ikeda M, Arai Y, Park SJ, et al. Prospective study of transcatheter arterial chemoeoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490–500.
9. Bekoc AT, Rivera-Sanfeliz G, Dufour CA, et al. Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation World J Urol. 2016 Aug 2 [Epub ahead of print]
10. Llovet JM, Decaens T, Roail JL, et al. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132. Epub 2010 Feb 19. Review.
11. Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res. 2013;19:1312–4. doi:10.1158/1078-0432.CCR-12-3796. Epub 2013 Feb 4.
12. Dindo D, Demantines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
13. Huang WC, Huang WC, Elkin EB, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181:55–61. doi:10.1016/j.juro.2008.09.017. discussion 61–2. Epub 2008 Nov 13.
14. Van Poppel H, Da Pozzo L, Albrecht W, et al. European Organization for Research and Treatment of Cancer (EORTC); National Cancer Institute of Canada Clinical Trials Group (NCIC CTG); Southwest Oncology Group (SWOG); Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007;51:1606–15. Epub 2006 Nov 15.
15. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168:2212–8. doi:10.1001/archinternmed.2008.22212.
16. Ukimura O, Kawauchi A, Fujito A, et al. Radio-frequency ablation of renal cell carcinoma in patients who were at significant risk. Int J Urol. 2004;11:1051–7.
17. Hiraoka K, Kawauchi A, Nakamura T, et al. Radiofrequency ablation for renal tumors: our experience. Int J Urol. 2009;16:689–73. doi:10.1111/j.1442-2042.2009.02537.x. Epub 2009 Sep 3.
18. Mura H, Yamagami T, Tanaka O, et al. CT findings after lipiodol marking performed before video-assisted thoracoscopic surgery for small pulmonary nodules. Acta Radiol. 2016;57:303–10. doi:10.1080/02841851.15576047. Epub 2015 Mar 19.
19. Miller JM, Julien P, Wachsman A, et al. The role of embolization in reducing the complications of cryoablation in renal cell carcinoma. Clin Radiol. 2014;69:1045–9. doi:10.1016/j.crad.2014.05.010. Epub 2014 Jul 16.
20. Bodily KD, Atwell TD, Mandrekar JN, et al. Hydrodisplacement in the percutaneous cryoablation of 50 renal tumors. Am J Roentgenol. 2010;194:779–83.
21. Atwell TD, Farrell MA, Leibovich BC, et al. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. 2008;179:2136–41.
22. Kapoor A, Tourne NJ, Dib RE. Review of the efficacy and safety of cryoablation for the treatment of small renal masses. Can Urol Assoc J. 2013;7:E38–44. doi:10.5489/cuaj.12018.
23. Gill IS, Rimer EM, Hasan WA, et al. Renal cryoablation: outcome at 3 years. J Urol. 2005;173:1903–7. http://dx.doi.org/10.1016/j.juro.2005.01.005. Epub 2005 Feb 16. doi:10.1016/j.juro.2005.01.005. Epub 2005 Feb 16.
24. Park JH, Kim SH, Han JK, et al. Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil. Cardiovasc Intervent Radiol. 1994;17:323–7.
25. Finlay DS, Beck S, Box G, et al. Percutaneous and laparoscopic cryoaulation of small renal masses. J Urol. 2008;180:492–8. discussion 8.
26. Lee SJ, Choyke LT, Locklin JK, et al. Use of hydrodissection to prevent nerve and muscular damage during radiofrequency ablation of kidney tumors. J Vasc Interv Radiol. 2006;17:1967–9.
27. Brashears III JH, Raj GV, Ciscia A, et al. Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model. J Urol. 2005;27:2160–5.
28. Wolldrich JM, Palazzi K, Stroup SP, et al. Trends in the surgical management of localized renal masses: thermal ablation, partial and radical nephrectomy in the USA, 1998–2008. BJU Int. 2013;111:1261–8. doi:10.1111/j.1464-410X.2012.11497.x. Epub 2013 Mar 7.